(NASDAQ: VSTM) Verastem's forecast annual revenue growth rate of 155.53% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.01%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Verastem's revenue in 2025 is $10,000,000.On average, 3 Wall Street analysts forecast VSTM's revenue for 2025 to be $991,832,519, with the lowest VSTM revenue forecast at $721,482,602, and the highest VSTM revenue forecast at $1,258,335,993. On average, 4 Wall Street analysts forecast VSTM's revenue for 2026 to be $4,715,188,278, with the lowest VSTM revenue forecast at $3,013,961,975, and the highest VSTM revenue forecast at $6,666,433,304.
In 2027, VSTM is forecast to generate $9,304,542,956 in revenue, with the lowest revenue forecast at $6,630,166,852 and the highest revenue forecast at $13,503,209,036.